Skip to main content

Zymeworks Inc(ZYME-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low23.68
Day High25.75
Open:25.09
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Zymeworks Inc

Select a category then submit the form to load news
Tipranks
Analysts’ Top Healthcare Picks: Zymeworks (ZYME), AbbVie (ABBV)
Tipranks
Truist Financial Keeps Their Buy Rating on Zymeworks (ZYME)
Tipranks
Stifel Nicolaus Reaffirms Their Buy Rating on Zymeworks (ZYME)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Veeva Systems (VEEV), Zymeworks (ZYME) and Senseonics Holdings (SENS)
Tipranks
Zymeworks’ Growth Clouded by High Clinical Failure Risk and Regulatory Uncertainty
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Zymeworks Monetizes Ziihera Royalties to Boost Liquidity
Tipranks
Zymeworks Posts Strong 2025 Growth and Bolsters Liquidity
Motley Fool
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript
GlobeNewswire
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
GlobeNewswire
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
GlobeNewswire
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Motley Fool
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
Tipranks
Citi Reaffirms Their Buy Rating on Zymeworks (ZYME)
Tipranks
Zymeworks Sets Date for 2025 Results and Corporate Update
GlobeNewswire
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
Tipranks
Zymeworks to Spotlight Pipeline and Portfolio at Series of Major Healthcare Investor Conferences
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Zymeworks (ZYME), Centessa Pharmaceuticals (CNTA)
Tipranks
Zymeworks Reshapes Board and Executive Team to Support Next Phase of Growth
Tipranks
Zymeworks Sets 2026 Strategy on Zanidatamab Momentum, ADC Pipeline and Cash-Fueled Growth
GlobeNewswire
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
GlobeNewswire
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Tipranks
Zymeworks’ Ziihera Sets New Survival Benchmark in First-Line HER2-Positive Gastric Cancer Trial
GlobeNewswire
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
Tipranks
Zymeworks Shareholders Back Directors, Executive Pay and Auditor
Tipranks
Positive Report for Zymeworks (ZYME) from Wells Fargo
Tipranks
Zymeworks (ZYME) Receives a Buy from Citi
Tipranks
Zymeworks to Showcase Innovative Biotherapeutics at Upcoming Conferences
GlobeNewswire
Zymeworks Announces Participation in Upcoming Conferences
Tipranks
Zymeworks to Engage in Key Investor Conferences
The Globe and Mail
Zymeworks wanted to be Canada’s first Big Pharma. Despite two blockbusters-in-the-making, that’s no longer the plan
Kenneth Galbraith, chief executive officer and Chair of board of Zymeworks Inc., in Cambridge, England last Thursday.

Profile

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.